ABL Europe - GMP manufacturing of viral vectors from non-adherent cell cultures
A new production facility for the GMP manufacture of viral vectors from non-adherent cell cultures is opening in Strasbourg, France. This will alleviate growing concerns that a lack of suitable manufacturing capacity is restricting the speed with which this nascent industry is able to bring viral vector products from the laboratory to the patient.
Fully Integrated Service Offering
Patrick Mahieux, General Manager of ABL (Advanced Bioscience Laboratories) Europe, the contract manufacturing organization responsible for the site expansion said, “The introduction of non-adherent cell culture capacity complements our existing adherent cell culture viral vector production technologies. It is the only pure-play, dedicated viral vector production site capable of manufacturing drug substance and drug product materials for toxicological studies, all clinical phases and even commercial launch. Everything from process development, manufacturing and QC release testing is performed under one roof.”